Biotechnology company Transgene (Euronext Paris: TNG) and NEC Corporation (NEC; TSE: 6701), an IT and network technology company, on Tuesday reported the presentation of new immunological data on TG4050, an individualised cancer vaccine, at the ASCO 2023 Annual Meeting.

TG4050 was developed using Transgene's myvac platform and NEC's AI capabilities. The vaccine induces specific immune responses against head and neck carcinoma in patients. It leverages viral vector technology to stimulate the patient's immune system and target solid tumours.

NEC's AI-driven Neoantigen Prediction System is used to identify and select immunogenic sequences for TG4050.

The data shows that all patients treated with TG4050 in an ongoing Phase I trial have developed a specific immune response and remain in remission. This indicates the potential of TG4050 as an adjuvant treatment for head and neck cancer.

Also, the data demonstrates that TG4050 induces strong immune responses against targeted antigens, even in patients with unfavorable systemic immunity and tumour micro-environment.

All patients who received TG4050 in the trial remain disease-free, showcasing its efficacy compared to the control arm.

Transgene and NEC are preparing for a Phase II trial in head and neck cancer, aiming to initiate it in the second half of 2023.

In addition, TG4050 is also being evaluated in a Phase I trial for ovarian cancer.